Bio Preventive Medicine to ship DNlite-IVD103

Taiwan-based Bio Preventive Medicine (BPM) has disclosed it has obtained the EU's CE IVD (in vitro diagnostics) mark for its DNlite-IVD103 reagent used to predict diabetes patients' diabetic nephropathy, and has signed with Austria-based sales agents to begin shipping DNlite-IVD130 in mid-June.

By detecting changes in a specific urinary biomarker and monitoring translational modification of the biomarker, DNlite-IVD130 can predict kidney conditions of a diabetes patient over 1-2 years, BPM said.

DNlite-IVD130 will be used on a trial basis at diabetes centers in Austria and Germany initially, BPM noted. As Germany is the largest and most advance medical market in Europe, BPM hopes that the trial use is a pilot for adoption of DNlite-IVD130 in other EU countries, company chairman and CEO Karen Tseng indicated.

BPM is expected to soon obtain official licenses for DNlite-IVD130 in other markets including Malaysia and Singapore.

BPM showcased DNlite-IVD130 at the virtual congress of ERA (European Renal Association)-EDTA (European Dialysis and Transplant Association) during June 6-9, 2020 and is attending North America-based BIO Digital One-on-One Partnering during June 8-12.

BPM's DNlite-IVD103
Photo: Company


About Bio Preventive Medicine (BPM):

Bio Preventive Medicine (BPM) is a leading-edge developer of biomarker solutions and technology.  BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs.  The company’s expertise in Diabetic Kidney Disease (DKD) and non-proteinuric renal disease led to the development of breakthrough technology DNlite-IVD103, the world’s first regulatory-approved non-invasive urinary test for predicting the progression of DKD. For more information, please refer to BPM official website:

Press Release: June 10, 2020


Bio Preventive Medicine to ship DNlite-IVD103 2020.06.10 DIGITIMES